Girish Venkataraman to Protein Kinase Inhibitors
This is a "connection" page, showing publications Girish Venkataraman has written about Protein Kinase Inhibitors.
Connection Strength
0.060
-
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J. 2021 02 18; 11(2):39.
Score: 0.035
-
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. 2016 Oct 18; 7(42):68833-68841.
Score: 0.026